Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01342341 · ClinicalTrials.gov registry record · Phase 4

Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake

A Phase 4 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 4
Development phase
48
Enrollment target

NCT01342341: Completed Phase 4 study, sponsored by University of California, San Francisco.

NCT01342341 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 48 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01342341, a Phase 4 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 4
Development phase
48 participants
Enrollment target

Study Summary

The overall goals of this study are to (1) expand knowledge about interactions of chlorzoxazone with alcohol by assessing the effects of chlorzoxazone compared to placebo in moderate and heavy social alcohol users and (2) to compare the effects of chlorzoxazone on visual cue induced alcohol craving to placebo in moderate to heavy social alcohol users.

Primary Outcome

Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study. The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption. Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.

Interventions

  • DRUG Parafon Forte

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2011-04
Est. Completion 2013-12
Phase Phase 4

What the finished NCT01342341 record still lists

NCT01342341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Parafon Forte is the first listed.

NCT01342341 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01342341 about?

NCT01342341 is a clinical study titled "Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake". The overall goals of this study are to (1) expand knowledge about interactions of chlorzoxazone with alcohol by assessing the effects of chlorzoxazone compared to placebo in moderate and heavy social alcohol users and (2) to compare the effects of chlorzoxazone on visual cue induced alcohol craving ...

What is the current status of trial NCT01342341?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2011-04. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01342341?

The interventions under investigation include: Parafon Forte (DRUG).

Who is sponsoring clinical trial NCT01342341?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01342341's enrollment target sits among peer trials

48 1331st of 2000 higher than 653 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01342341, the US trial registry maintained by the National Library of Medicine. NCT01342341 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.